Precision Biosciences and Imugene have concluded a strategic transaction for worldwide rights to Precision’s allogeneic CAR T candidate, Azercabtagene Zapreleucel (azer-cel), for cancer.
Imugene will manage the ongoing clinical implementation of azer-cel for patients with large B-cell lymphoma (LBCL) who have relapsed after autologous CAR T treatment.
The licence also covers an option for the development of up to three other cancer research programmes in the coming years.
Precision will receive upfront funding of $21m, comprising both cash and equity, in return for worldwide rights to azer-cel.
The company could also receive an $8m near-term payment in cash and equity once Phase Ib dosing is successfully completed in the CAR T relapsed LBCL patient group.
Precision will potentially earn $198m in extra milestone payments, along with double-digit royalties based on net sales for azer-cel.
The company can also receive up to $145m in milestone payments and tiered royalties on net sales for each additional research programme chosen by Imugene.
Precision BioSciences CEO Michael Amoroso stated: “We are very pleased to partner with Imugene as they plan to leverage azer-cel’s clinical data package and recent regulatory feedback to continue its path toward a pivotal trial in LBCL and potentially help patients in dire need.
“Our commercial and scientific interests are closely aligned, and we believe Precision’s allogeneic CAR T technology can complement the novel oncology approaches being pursued by Imugene, especially its OnCARlytics platform for solid tumours.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Source link
#Precision #Imugene #conclude #transaction #cancer #treatment
